MRUS vs. VTRS, UTHR, SRPT, RDY, CTLT, ROIV, ELAN, ASND, LEGN, and CERE
Should you be buying Merus stock or one of its competitors? The main competitors of Merus include Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.
Viatris has a net margin of -0.37% compared to Viatris' net margin of -390.36%. Merus' return on equity of 16.63% beat Viatris' return on equity.
Viatris currently has a consensus target price of $11.00, indicating a potential upside of 3.77%. Merus has a consensus target price of $63.80, indicating a potential upside of 19.83%. Given Viatris' stronger consensus rating and higher probable upside, analysts plainly believe Merus is more favorable than Viatris.
Viatris has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
In the previous week, Merus had 22 more articles in the media than Viatris. MarketBeat recorded 27 mentions for Merus and 5 mentions for Viatris. Viatris' average media sentiment score of 0.41 beat Merus' score of -0.07 indicating that Merus is being referred to more favorably in the news media.
Merus received 309 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 65.61% of users gave Merus an outperform vote while only 35.59% of users gave Viatris an outperform vote.
79.9% of Viatris shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 4.6% of Merus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Viatris has higher revenue and earnings than Merus. Viatris is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
Summary
Merus beats Viatris on 11 of the 18 factors compared between the two stocks.
Get Merus News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
